Number 828 • December 2019

# Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Pinaverium 100 mg Tablet (DIN 02469685) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 3, 2020**.

# **PINAVERIUM BROMIDE**

### **100 MG TABLET**

 00002469685
 APO-PINAVERIUM
 APX
 \$ 0.5346

 00002230684
 DICETEL
 BGP
 \$ 0.6419

Alberta Blue Cross has been advised by AA Pharma Inc. that the shortage for Desmopressin 10 mcg/dose Nasal Spray (DIN 02242465) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 3, 2020**.

# **DESMOPRESSIN ACETATE**

### 10 MCG / DOSE NASAL METERED DOSE SPRAY

00002242465	DESMOPRESSIN	AAP	\$ 1.5222
00000836362	DDAVP	FEI	\$ 1.9796

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Phenytoin 25 mg/ml Oral Suspension (DIN 02250896) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 6, 2020**.

# **PHENYTOIN**

# 25 MG / ML ORAL SUSPENSION

00002250896	TARO-PHENYTOIN	TAR	\$ 0.0428
00000023450	DILANTIN-125	PFI	\$ 0.0571

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Benzoyl Peroxide/Clinda Kit 5%/1% Topical Gel (DIN 02464519) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 8, 2020**.

### CLINDAMYCIN PHOSPHATE/ BENZOYL PEROXIDE

#### 1 % / 5 % TOPICAL GEL

00002464519	TARO-BENZOYL PEROXIDE/CLINDAMYCIN KIT	TAR	\$ 0.7422
00002248472	BENZACLIN	VCL	\$ 1.0141

Alberta Blue Cross has been advised by Auro Pharma Inc., Sandoz Canada Inc., Sanis Health Inc, Sivem Pharmaceuticals ULC and Teva Canada Limited that the shortages for Auro-Venlafaxine XR 150 mg Extended-Release Capsule (DIN 02452855), Sandoz Venlafaxine XR 150 mg Extended-Release Capsule (DIN 02310333), Venlafaxine XR 150 mg Extended-Release Capsule (DIN 02354748), Venlafaxine XR 150 mg Extended-Release Capsule (DIN 02385945) and Teva-Venlafaxine XR 150 mg Extended-Release Capsule (DIN 02275058) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 8, 2020**.

### **VENLAFAXINE HCL**

### 150 MG EXTENDED-RELEASE CAPSULE

00002331705	APO-VENLAFAXINE XR	APX	\$ 0.1927
00002452855	AURO-VENLAFAXINE XR	AUR	\$ 0.1927
00002278561	PMS-VENLAFAXINE XR	PMS	\$ 0.1927
00002380099	RAN-VENLAFAXINE XR	RAN	\$ 0.1927
00002310333	SANDOZ VENLAFAXINE XR	SDZ	\$ 0.1927
00002275058	TEVA-VENLAFAXINE XR	TEV	\$ 0.1927
00002354748	VENLAFAXINE XR	SNS	\$ 0.1927
00002385945	VENLAFAXINE XR	SIV	\$ 0.1927
00002237282	EFFEXOR XR	PFI	\$ 2.1124

# When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** ab.bluecross.ca/providers/pharmacy-home.php



